{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:19:50Z","timestamp":1792642790738,"version":"4.5.0"},"reference-count":68,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2021,4,3]]},"DOI":"10.1080\/09546634.2019.1654075","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T10:37:10Z","timestamp":1565260630000},"page":"277-285","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":144,"title":["Acne vulgaris: new evidence in pathogenesis and future modalities of treatment"],"prefix":"10.1080","volume":"32","author":[{"given":"Neirita","family":"Hazarika","sequence":"first","affiliation":[{"name":"Department of Dermatology","place":["Rishikesh, India"]},{"name":"All India Institute of Medical Sciences","place":["Rishikesh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60321-8"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5020"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3870"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-013-1374-4"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0009922809342462"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087806"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04299.x"},{"key":"e_1_3_2_9_1","first-page":"18","article-title":"Acne vulgaris and the epidermal barrier: is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and\/or functional integrity of the epidermal barrier?","volume":"6","author":"Thiboutot D","year":"2013","unstructured":"Thiboutot D, Del Rosso JQ. Acne vulgaris and the epidermal barrier: is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and\/or functional integrity of the epidermal barrier? J Clin Aesthet Dermatol. 2013;6:18\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01262335"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.3.8473"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13186"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.9.6957"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S69135"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/AHMT.S55832"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13634"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10897.x"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12329907"},{"key":"e_1_3_2_19_1","first-page":"4","article-title":"Physiopathology of acne vulgaris: recent data, new understanding of the treatments","volume":"14","author":"Pawin H","year":"2004","unstructured":"Pawin H, Beylot C, Chivot M, et\u00a0al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol. 2004;14:4\u201312.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06933.x"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12224"},{"key":"e_1_3_2_22_1","first-page":"20","article-title":"The expression of toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical toll-like receptor modulators","volume":"3","author":"Valins W","year":"2010","unstructured":"Valins W, Amini S, Berman B. The expression of toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical toll-like receptor modulators. J Clin Aesthet Dermatol. 2010;3:20\u201329.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.3.1535"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2003.01588.x"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.1220"},{"key":"e_1_3_2_26_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier: NCT02682264 An open-label long-term extension study to evaluate the safety of CB-03-01 cream 1% in participants with acne vulgaris; 2016 February 15 [cited 2018 Feb 1]; [about 4 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02682264"},{"key":"e_1_3_2_27_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier: NCT00525499 A phase 2 study of ASC-J9 cream in acne vulgaris; 2007 Sep 5 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00525499"},{"key":"e_1_3_2_28_1","unstructured":"Kelce W. Topical nitric oxide: a first class local antiandrogen therapy (White Paper). Novan Therapeutics; [cited 2018 Mar 23]. Available from: http:\/\/www.novantherapeutics.com\/files\/8613\/7398\/9326\/Topical_nitric_oxide_local_androgen_therapy.pdf"},{"key":"e_1_3_2_29_1","first-page":"12","article-title":"Results of a phase 2 efficacy and safety study with SB204, an investigational topical nitric oxide-releasing drug for the treatment of acne vulgaris","volume":"9","author":"Baldwin H","year":"2016","unstructured":"Baldwin H, Blanco D, McKeever C, et\u00a0al. Results of a phase 2 efficacy and safety study with SB204, an investigational topical nitric oxide-releasing drug for the treatment of acne vulgaris. J Clin Aesth Dermatol. 2016;9:12\u201318.","journal-title":"J Clin Aesth Dermatol"},{"key":"e_1_3_2_30_1","first-page":"369","article-title":"The medicinal action of androgens and green tea epigallocatechin gallate","volume":"7","author":"Liao S.","year":"2001","unstructured":"Liao S. The medicinal action of androgens and green tea epigallocatechin gallate. Hong Kong Med J. 2001;7:369\u2013374.","journal-title":"Hong Kong Med J"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.202"},{"key":"e_1_3_2_32_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier: NCT01687556 Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes; 2012 September 19 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01687556"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.923401"},{"key":"e_1_3_2_34_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier: NCT01492647 A study of JNJ 10229570-AAA to evaluate safety and tolerability in Japanese participants with acne vulgaris; 2011 December 15 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01492647"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.3.8368"},{"key":"e_1_3_2_36_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier: NCT00098358 Study of oral zileuton in the treatment of moderate to severe facial acne vulgaris; 2004 December 8 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00098358"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1337745"},{"key":"e_1_3_2_38_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier: NCT02385760 CTX-4430 for the treatment of moderate to severe facial acne vulgaris; 2015 Mar 11 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02385760"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.06.009"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12097"},{"key":"e_1_3_2_41_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01293552 Clinical trial to evaluate ANT-1207 in subjects with acne; 2011 Feb 10 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01293552"},{"key":"e_1_3_2_42_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT03127956 A long-term safety study of Olumacostat Glasaretil gel in subjects with acne vulgaris; 2017 April 25 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03127956"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.29"},{"key":"e_1_3_2_44_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT02502669 Finasteride treatment of severe nodulocystic acne; 2015 Jul 20 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02502669"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0022-3565(24)39233-X","article-title":"R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents","volume":"293","author":"Stoppie P","year":"2000","unstructured":"Stoppie P, Borgers M, Borghgraef P, et\u00a0al. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther. 2000;293:304\u2013312.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07896.x"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2004.05762.x"},{"key":"e_1_3_2_48_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01474798 Phase II trial of RA-18C3 in subjects with moderate to severe acne vulgaris; 2011 Nov 18 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01474798"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.40"},{"key":"e_1_3_2_50_1","first-page":"333","article-title":"Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study","volume":"17","author":"Leyden JJ","year":"2018","unstructured":"Leyden JJ, Sniukiene V, Berk DR, et\u00a0al. Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study. J Drugs Dermatol. 2018;17:333\u2013338.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2015.4"},{"key":"e_1_3_2_52_1","first-page":"1235","article-title":"Zolav(\u00ae) (a p-carboethoxy-tristyrylbenzene derivative) [corrected]: a new antibiotic for the treatment of acne","volume":"10","author":"Dinant A","year":"2016","unstructured":"Dinant A, Boulos RA. Zolav(\u00ae) (a p-carboethoxy-tristyrylbenzene derivative) [corrected]: a new antibiotic for the treatment of acne. Drug Des Dev Ther. 2016;10:1235\u20131242.","journal-title":"Drug Des Dev Ther"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.131-136.2005"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05552-11"},{"key":"e_1_3_2_55_1","first-page":"677","article-title":"Topical treatment with an agent disruptive to P. acnes biofilm provides positive therapeutic response: results of a randomized clinical trial","volume":"15","author":"Bernhardt MJ","year":"2016","unstructured":"Bernhardt MJ, Myntti MF. Topical treatment with an agent disruptive to P. acnes biofilm provides positive therapeutic response: results of a randomized clinical trial. J Drugs Dermatol. 2016;15:677\u2013683.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_56_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT00211523 Safety and efficacy of MBI 226 2.5% and 5.0% topical acne solutions in the treatment of acne; 2005 Sep 21 [cited 2018 Feb 1]; [about 3 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00211523"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1159\/000439439"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151184"},{"key":"e_1_3_2_59_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT00714454 5% sodium l-ascorbyl-2-phosphate lotion for the treatment of acne vulgaris; 2008 Jul 14 [cited 2018 Feb 1]; [about 4 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00714454"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1586\/edm.10.42"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.277"},{"key":"e_1_3_2_62_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01074502 Apremilast in the treatment of moderate to severe acne; 2010 Feb 24 [cited 2018 Feb 1]; [about 6 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01074502"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-015-0072-7"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.13989"},{"key":"e_1_3_2_65_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01498874 Efficacy and safety study of Gevokizumab to treat moderate to severe acne vulgaris; 2011 Dec 20 [cited 2018 Feb 1]; [about 4 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01498874"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105238"},{"key":"e_1_3_2_67_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT02998671 Study of efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne; 2016 Dec 20 [cited 2018 Feb 1]; [about 5 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02998671"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.113959"},{"key":"e_1_3_2_69_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01694433 Clinical trial to determine the efficacy of vitamin D for acne therapy; 2012 Sep 27 [cited 2018 1]; [about 4 screens]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01694433"}],"container-title":["Journal of Dermatological Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09546634.2019.1654075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T19:25:00Z","timestamp":1770924300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546634.2019.1654075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4,3]]}},"alternative-id":["10.1080\/09546634.2019.1654075"],"URL":"https:\/\/doi.org\/10.1080\/09546634.2019.1654075","relation":{},"ISSN":["0954-6634","1471-1753"],"issn-type":[{"value":"0954-6634","type":"print"},{"value":"1471-1753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}